Ultimovacs ASA at ABGSC Investor Days Transcript
Hi. My name is Adam Karlsson. I'm a healthcare analyst here at ABG, and it's my pleasure to introduce the next company and the next presenter, which is Carlos de Sousa, CEO of Ultimovacs. Carlos, the floor is yours.
Thank you, Adam, and good afternoon, everybody. I'm the CEO of Ultimovacs, a biotech company located in Oslo. We have 26 employees.
If we can move to the next slide. As we are a publicly listed company, I need to show you this slide, but we can move to the next one. As a company, we operate in the treatment of cancer with what we call next-generation universal cancer vaccine. Our vaccine boosts the anti-tumor response. What does this mean? This means that we help the immune system to identify and kill cancer cells. And we do this by recognizing a special target in the cancer cells called telomerase, and 85% to 90% of cancers in all stages of disease express this telomerase.
And we are a truly off-the-shelf vaccine, ready to be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
